| Fund ID | 805-2697265273 |
| Fund type | Venture Capital Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 0% |
| Owned by the adviser or related persons | 1% |
| Owned by funds of funds | 21% |
| Owned by non-U.S. persons | 0% |
| Fund | Type | Gross assets |
|---|---|---|
| Oncology Impact Fund 2, L.P. | Other Private | $1.01B |
| UBS Oncology Impact Fund L.P. | Other Private | $629.7M |
| Mpm Bioventures 2018, L.P. | Venture Capital | $548.7M |
Mpm Bioventures 2014 (b), L.P. reports $7.5 million in gross assets, among the top 80% of private funds by size.
The stated minimum investment is $50,000.
Mpm Bioventures 2014 (b), L.P. is managed by Mpm Asset Management LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.